Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

@article{Tacar2013DoxorubicinAU,
  title={Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems},
  author={Oktay Tacar and P. Sriamornsak and C. Dass},
  journal={Journal of Pharmacy and Pharmacology},
  year={2013},
  volume={65}
}
Objectives  The frontline drug doxorubicin has been used for treating cancer for over 30 years. While providing a cure in select cases, doxorubicin causes toxicity to most major organs, especially life‐threatening cardiotoxicity, which forces the treatment to become dose‐limiting. 
Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Doxorubicin‐induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?
Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
Doxorubicin: the good, the bad and the ugly effect.
Molecular biology of doxorubicin-induced cardiomyopathy.
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
Oncogenes as Novel Targets for Cancer Therapy (Part IV)
Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
...
1
2
3
4
5
...